These ratings are submitted by site users and should be used for information only.
They do not constitute any instruction to trade and do not reflect the opinion of this site.
What do the charts indicate?
The colour of the lines on the chart indicate the performance of the rating based upon the price at the point the rating was submitted. More information »
Money at last for Sareum. All good things to those that wait. Kinase inhibitors are big money nowadays with commercial versions adding as much as $5 billion to an acquisition deal e.g., Onyx. Sareum has a great development tie up with SRI international as well so expect some fireworks ahead share-price-wise. r Strong BUY
Judging from the guest list of invited speakers announced today Scancell's Moditope is to get some serious attention from cancer treatment specialists. Great future for this discovery. Well done Scancell!
Scancell has played a blinder inviting Prof. Karol Sikora to head its guest speaker list on Investor Day, 1st October. The guy is hugely controversial and attracts a crowd of journalists wherever he goes. Ideal for Scancell's planned introduction to their Moditope discovery. Big occasions mean big publicity. This stock is a massive BUY